Latest News
& Press Releases

After months of ongoing testimony from various whistleblowers and investors, Elizabeth Holmes, Theranos founder and CEO, has finally taken the witness stand in her fraud trial.

It’s been a busy week so far, with new discovery facilities launched in the biotech space.

ARO-HSD will be evaluated in a Phase I/II trial that will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of its ability to target HSD17B13 as a treatment for NASH.

If you are wondering what the butterfly effect is and how it affects COVID-19 patients, you have come to the right place. Here is everything you need to know.

Before going for pharmaceutical jobs interviews, you should be prepared to give the best answers possible. Here are six questions you should be ready for.

Even before the drug’s approval on June 7, there were cases of amyloid-related imaging abnormalities (ARIA-E), or cerebral edema, observed in the trials.

Twist Bioscience snapped up in vivo antibody discovery company Abveris Inc. in a deal valued at up to $190 million. The acquisition is expected to bolster Twist’s biopharma antibody capabilities.

Under the strategic collaboration, Neurocrine Biosciences and Sosei Group Corporation will develop and commercialize novel muscarinic receptor agonists to treat the said illnesses.

After indicating it might entertain a sale, Novartis may receive an offer from investment group EQT and the Struengmann family for its generic unit Sandoz.

News on COVID-19 vaccine developments and disease studies continue to deliver highs and lows. Here are some of the more recent happenings.

The FDA has granted Cambridge-based bluebird Bio a Priority Review of its Biologics License Application for betibeglogene autotemcel (beti-cel).

Connect Biopharma shares plummeted 55% despite reported positive topline data from its Phase II trial of CBP-201 for adults with moderate-to-severe atopic dermatitis.

Acceptance of TempraMed’s products by Meuhedet Health Services strengthens TempraMed’s B2B institutional commercialization strategy as the Company advances reimbursement initiatives and expands relationships with leading healthcare organizations globally Highlights Meuhedet Health Services, Israel’s third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed’s flagship VIVI Cap™ and VIVI Epi™ products. TempraMed products are now accepted by two of Israel’s four national HMOs—Maccabi Healthcare Services and Meuhedet—providing institutional access to approximately four million insured lives. The Company is executing a global B2B institutional strategy focused on healthcare organizations, insurers, distributors and government healthcare systems.

· New research team expands capabilities at Boehringer’s U.S. R&D site in Ridgefield, Connecticut.